Inhibiting the expression of ARID1B significantly reduces the proliferation, migration and invasive ability of bladder cancer cells, suggesting that it could serve as a potential prognostic biomarker for urothelial carcinoma of the bladder and aid in patient selection for adjuvant chemotherapy [22]. The gene discussed is ARID1B; the disease is urinary bladder cancer.